MedPAC’s Part B Options Include ‘Value-Based’ Payment During Accelerated Approval
Executive Summary
Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.
You may also be interested in...
US Medicare Part D Inflation Is Real, MedPAC Rebate Data Show
The US Medicare Payment Advisory Commission shares its first looks at the impact of rebates in the Medicare Part D program. Rebates do indeed distort the overall spending trends, the analyses suggest – but underlying prices are still increasing relatively quickly.
Reforming Accelerated Approval: Three Ideas For Congress
Ideas to reform Accelerated Approval are likely to be debated during the reauthorization of the key US FDA user fee funding authority in 2022. Here are three suggestions for Congress to consider.
Medicare’s Draft Policy For Alzheimer’s Drugs And The Question Of Cost
Critics of the US Centers for Medicare and Medicaid Services’ proposed decision to restrict Medicare coverage of Aduhelm and similar Alzheimer’s drugs have described the policy as an effort to ration treatments based on cost concerns. Even some supporters are connecting cost to the decision.